Bank of America’s Moleculin Biotech MBRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-36
| Closed | -$119 | – | 6412 |
|
|
2025
Q4 | $119 | Buy |
36
+25
| +227% | +$233 | ﹤0.01% | 6794 |
|
|
2025
Q3 | $141 | Buy |
11
+5
| +83% | +$68 | ﹤0.01% | 7787 |
|
|
2025
Q2 | $44 | Buy |
6
+5
| +500% | +$103 | ﹤0.01% | 8127 |
|
|
2025
Q1 | $31 | Sell |
1
-3
| -75% | -$101 | ﹤0.01% | 8060 |
|
|
2024
Q4 | $176 | Sell |
4
-2
| -33% | -$121 | ﹤0.01% | 7619 |
|
|
2024
Q3 | $406 | Buy |
6
+5
| +500% | +$360 | ﹤0.01% | 7424 |
|
|
2024
Q2 | $99 | Buy |
+1
| New | +$115 | ﹤0.01% | 7701 |
|
|
2024
Q1 | – | Hold |
0
| – | – | – | 7456 |
|
|
2023
Q4 | – | Hold |
0
| – | – | – | 7400 |
|
|
2023
Q3 | – | Hold |
0
| – | – | – | 7520 |
|
|
2023
Q2 | – | Sell |
-18
| Closed | -$4.75K | – | 7456 |
|
|
2023
Q1 | $6.48K | Hold |
18
| – | – | ﹤0.01% | 7009 |
|
|
2022
Q4 | $7.08K | Hold |
18
| – | – | ﹤0.01% | 6991 |
|
|
2022
Q3 | $7K | Hold |
18
| – | – | ﹤0.01% | 7309 |
|
|
2022
Q2 | $10K | Hold |
18
| – | – | ﹤0.01% | 7391 |
|
|
2022
Q1 | $12K | Hold |
18
| – | – | ﹤0.01% | 7680 |
|
|
2021
Q4 | $12K | Hold |
18
| – | – | ﹤0.01% | 7659 |
|
|
2021
Q3 | $20K | Hold |
18
| – | – | ﹤0.01% | 7386 |
|
|
2021
Q2 | $24K | Hold |
18
| – | – | ﹤0.01% | 7082 |
|
|
2021
Q1 | $27K | Hold |
18
| – | – | ﹤0.01% | 6812 |
|
|
2020
Q4 | $32K | Hold |
18
| – | – | ﹤0.01% | 6472 |
|
|
2020
Q3 | $33K | Hold |
18
| – | – | ﹤0.01% | 6162 |
|
|
2020
Q2 | $39K | Buy |
+18
| New | +$42.7K | ﹤0.01% | 6082 |
|
|
2019
Q2 | – | Sell |
-11
| Closed | -$20K | – | 7319 |
|
|
2019
Q1 | $20K | Hold |
11
| – | – | ﹤0.01% | 6498 |
|
|
2018
Q4 | $26K | Hold |
11
| – | – | ﹤0.01% | 6420 |
|
|
2018
Q3 | $40K | Hold |
11
| – | – | ﹤0.01% | 6297 |
|
|
2018
Q2 | $45K | Hold |
11
| – | – | ﹤0.01% | 6199 |
|
|
2018
Q1 | $45K | Hold |
11
| – | – | ﹤0.01% | 6084 |
|
|
2017
Q4 | $47K | Hold |
11
| – | – | ﹤0.01% | 6087 |
|
|
2017
Q3 | $60K | Hold |
11
| – | – | ﹤0.01% | 5867 |
|
|
2017
Q2 | $47K | Hold |
11
| – | – | ﹤0.01% | 5901 |
|
|
2017
Q1 | $29K | Hold |
11
| – | – | ﹤0.01% | 6155 |
|
|
2016
Q4 | $57K | Buy |
+11
| New | +$73.7K | ﹤0.01% | 5870 |
|
Other funds holding MBRX
SM
VCM
HF
VFT
TRCT
EI
Bank of America's MBRX Position: Q1 2026 in Review
Bank of America sold out of Moleculin Biotech (MBRX) in Q1 2026, closing a stake of 36 shares — an estimated $119 sold.
Bank of America first reported a position in MBRX in Q4 2016 and held it in 29 quarters. The position peaked at $60K in Q3 2017. 20 funds tracked by Wall St. Rank hold MBRX as of Q1 2026.
- Bank of America reported no remaining Moleculin Biotech position as of Q1 2026 after selling out during the quarter.
- Bank of America sold 36 Moleculin Biotech shares in Q1 2026, an estimated $119.
- Bank of America first reported a position in Moleculin Biotech in Q4 2016 and held it in 29 quarters.
- Bank of America's Moleculin Biotech position peaked at $60K in Q3 2017.
- 20 funds tracked by Wall St. Rank held Moleculin Biotech as of Q1 2026.
Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.